@Alf13.

Q1.
As apprvl yet to obtained frm NPRA

Answer 1:

Approval from NPRA is referred to a plan to distribute Sinopharm Covid-19 vaccine. Aproved or no approval by NPRA, it does not related to other plans.

Q2.
... wud dere b likelihood the comp abort/call off d Sung Master acquisition after competed d RI exercise

Answer 2:

Those two plans has different objectives.

a. RI exercises been setup among others to be used to finance the proposed acquisition of
126 units of proposed serviced apartments located in Genting Highlands and the group's new construction business.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3166029

b. Sung Master acquisition will be satisfied via cash, an allotment and issuance of a number of new shares to Sung Master and proposed subscription of a number of new shares by Mr Kuah Choon Ching.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3174495

Conclusions:

1. The success of the Sinopharm Covid-19 vaccine distributorship plan will be subjected to NPRA's approval, and not related to the success of their RI exercises.

2. The failures of their RI exercises will only affect their related plans, especially the plan to acquire the proposed acquisition of Genting Highland appartments.

3. I think, as the proposed Sung Master acquisition has been approved in EGM and the sources of financing for the plan is not from the RI exercises, therefore the risks for the plan to be terminated is small.

After all, TAYOR.

@Alf13.

Q1.
As apprvl yet to obtained frm NPRA

Answer 1:

Approval from NPRA is referred to a plan to distribute Sinopharm Covid-19 vaccine. Aproved or no approval by NPRA, it does not related to other plans.

Q2.
... wud dere b likelihood the comp abort/call off d Sung Master acquisition after competed d RI exercise

Answer 2:

Those two plans has different objectives.

a. RI exercises been setup among others to be used to finance the proposed acquisition of
126 units of proposed serviced apartments located in Genting Highlands and the group's new construction business.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3166029

b. Sung Master acquisition will be satisfied via cash, an allotment and issuance of a number of new shares to Sung Master and proposed subscription of a number of new shares by Mr Kuah Choon Ching.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3174495

Conclusions:

1. The success of the Sinopharm Covid-19 vaccine distributorship plan will be subjected to NPRA's approval, and not related to the success of their RI exercises.

2. The failures of their RI exercises will only affect their related plans, especially the plan to acquire the proposed acquisition of Genting Highland appartments.

3. I think, as the proposed Sung Master acquisition has been approved in EGM and the sources of financing for the plan is not from the RI exercises, therefore the risks for the plan to be terminated is small.

After all, TAYOR.

GUYS, SORRY FOR KEEP RE POSTING THIS:

-----------------------

I WANT TO TEST MY SIMPLE THEORY OF THE RI EXERCISES ON KANGER:

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.


And:


I'm keep waiting for a good announcement from Kanger, BEFORE THE EX-DATE FOR THE RIGHT OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE FOR THE RIGHT ISSUE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>


AFTER ALL. TAYOR

-------- Kanger still pending approval from National Pharmaceutical Regulatory Agency (NPRA) for the import of vaccine.

Bermaksud, Kanger sepatutnya sudah buat permohonan kepada NPRA.
Adakah itu maksudnya?????

I think so. But both exercises will be done separately.

Mr Quah should subscribe this RI exercises first, as the undertakings of share subscription related to Sung Master acquisition will be executed after the RI exercises.

The Sung Master acquisition has been approved in the last EGM, but the execution of the proposed plan not yet executed.

@wistlebower99. I'm not qualified to advice on selling call or buying call in any securities transactions. He He.

@hlh1962. Yes. The new warrant also probably listed and ready for transaction on the same date.

Frankly, I will subscribe the RI shares only in a condition that the share price before the last date for acceptance and payment @ above 6 sen, for instance @ 7 sen above.

Others, maybe have different plan. TAYOR.

Trading Rights (OR) = 01 Sep 2021 - 7 Sep 2021
Last date for acceptance and payment = 15 Sep 2021 05:00 PM
Listing Date = 30 Sep 2021

whistlebower99 The company might settle for minimum subscription if the RI is under-subscribed.

-----------------
Therefore, It would be better for them to pop up the price to make sure more retailers subscribe the RI shares.

Furthermore, if the RI too much under subscribed, It's not good for the company's plan and for the overall overview of the company.

I think, they have to make sure that the RI will be a success.

TAYOR

@wistlebower99.

I still believe Kanger''s RI also will be a success.

I have a feeling that the price would be push up to more than 6 sen before the last date of subscription date.

If not, the RI I think will be a failure. If there is too much under subscription by retailers, there will be too much excess application has to be done by the substantial shareholders and directors.

TAYOR.

@nubiskubissss. You can find more if you search for it.

@nubiskubissss.

One of them. Look at some PP and RI done by Hong Seng. What is the state of Hong Seng right now. The company's price between 4.5 sen - RM1.67 (now)

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3147350

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3088507

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=2991320

@whistlebower99.

I hope you also can give a list of some companies which had a successful and progressing after executed their RI exercises.

Different companies has a different management............ which we can't simply judge it before it's become a reality.

Also, how high it can be before the last date of subscription?
It's a probability. Maybe. He He

@JK22. ... Unless a very very promising good news come around before RI expire.

-------------------

Agree.

@hlh1962. If today you have 100 lots of share, on 1/9 you share account will be added with 100 lots unit of OR. If you don't want to subscribe the RI, you can try to sell the OR from 1/9 up to 7/9.
After 7/9 you can't sell the OR anymore, but you can use the OR to covert it for RI shares.
If you don't sell or convert your OR for RI shares, after 15/9/2021 your OR become toilet papers.

If you want to subscribe the RI, you can't sell the OR. You can subscribe for 100 lots of shares by paying 6 sen for each OR, you will get one unit of RI share. The last date and time for payment for acceptance of the RI shares is on 15 Sep 2021 05:00 PM.

You can refer the incoming announcement/circular by Kanger to know how to subscribe the share.

Kanger, I think is still in the operator's games. There should be operators inside this fluctuations of the share price.

Let us see what will happen, especially towards the ex-date, 27 August 2021.


I believe the company must has the plans to make sure that the company will successfully executed the RI plan.

Anyway, investing is full of risks and opportunities. TAYOR.

To do business needs capital. There are many ways to acquire the capital. Without capital there is no chance to expand the company businesses. There is a number of plans for Kanger to venture in new businesses.

The company without enough cash in its account, can generate the capital needed by exercising a debt/loan financing. The company also can generate the capital to do new investments via the issuance of new shares by exercising PP or RI. It’s not involved any major debt/loan financing facilities and it’s a ZERO RISKS FINANCING exercises .

By doing so, the company can minimize the risks of higher debt burden by the company in the future. The financing facility via issuance of new shares also could minimize the cost of financing for the company.

IF the new businesses are truly have good potential to improve the revenue and profitability of the company, I think it will be for the good to the company and it share holders.

Furthermore, my logic is, the company with plans to do something for betterment of the company is better than the company without any plans. Yes, every investment has many risks but it also maybe has many opportunities.

@Peace99. I'm not good in the chart and market transaction analysis. But I think now Kanger is probably still in the operator's games.

If there is no operators inside, I think the volume of the transaction will be not so huge as that.

Let us see what will happen, especially towards Ex-date, 27 August 2021.

@Peace99. Agree. In most cases, it's will be like that.

I believe the company must has the plans to make sure that the company will successfully executed the RI plan.

Anyway, investing is full of risks and opportunities. TAYOR.

@dchin472. ...... bosses sure always give good story but u have to think how true is the story
-----------------------
All the bosses from every listed company which have a plan for the company will announce it to give good story about their plan.

THE REALITY IS, ARE WE COMPETENT ENOUGH TO JUDGE ANY COMPANY PLANS AS VIABLE OR NOT VIABLE?

WHETHER IT'S A TRUE STORY OR NOT, WE ONLY CAN READ IT BASED ON ITS PROGRESS AND FUTURE RESULTS.

To do business needs capital. There are many ways to acquire the capital. Without capital there is no chance to expand the company businesses. There is a number of plans for Fast to venture in new businesses.

The company without enough cash in its account, can generated the capital needed by exercising a debt/loan financing. The company also can generated the capital to do new investments via the issuance of new shares by exercising PP or RI. It’s not involved any major debt/loan financing facilities and it’s a ZERO RISKS FINANCING exercises .

By doing so, the company can minimize the risks of higher debt burden by the company in the future. The financing facility via issuance of new shares also could minimize the cost of financing for the company.

If the new businesses are truly have good potential to improve the revenue and profitability of the company, I think the big NOSH issues should be no issues at all.

Furthermore, my logic is, the company with plans to do something for betterment of the company is better than the company without any plans. Yes, every investment has many risks but it also maybe has many opportunities.

@dchin.

Why so afraid of a company with 1 billion or more shares?

Look at Hong Seng, it NOSH is 2.457 bil but its price is @RM1.70. For MY E.G, its NOSH will be 8 bil + after Bonus issue. Currently, MY E.G NOSH is 3.772 bil but its share price is @RM1.96.

Therefore, the most important aspects to be look at Fast should be the company's ability to improve its businesses, profitability and FA conditions.

If the company has a bright prospects because of exercising plans of businesses by uplifting the NOSH via right issue of shares or PP, I think it's a good move done by the company.

@whistlebower99.

I WANT TO TEST MY SIMPLE THEORY OF THE RI EXERCISES ON KANGER:

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.


And:


I'm keep waiting for a good announcement from Kanger, BEFORE THE EX-DATE FOR THE RIGHT OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE FOR THE RIGHT ISSUE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>


AFTER ALL. TAYOR

wistlebower99.

I'm here safe and sound. Thank God.

@18KHarmoni. Pelabur Solution pun sudah lama menunggu Solution dapat realisasikan plan jadi pengedar vaksin Sinovac. Sudah lama dah rancangan tu dibuat. Hari ini baru sampai, confirmed.

Kalau ada rezeki tu adalah nanti. Kalau langsung tak ada, memang con lah Kanger. He He

SORRY. Reposting idea only. JUST FOR NEWBIES...
He He.

Waiting for a good announcement from Kanger, BEFORE THE EX-DATE FOR THE RIGHT OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE FOR THE RIGHT ISSUE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>

United Arab Emirates
The UAE began production of Hayat-Vax, a locally manufactured version of China’s Sinopharm vaccine, in March 2021. Current plans include the production of 2 million doses per month, a majority of which will be exported to low-income countries, particularly Africa and the Middle East, under the WHO’s COVAX scheme.[47][48] By being produced in the UAE, Hayat-Vax is believed to be able to “resolve many of the issues plaguing public acceptance of other vaccines” in Middle Eastern countries.[49]

Solution Biologics is the product registration holder for CanSino in Malaysia.
-------------

If Solution Biologics can own the product registration holder for Covid-19 vaccine, Kanger also can be approved with Hayat-Vax vaccine product registration holder.

------------------

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

Hope the time will come. Sooner or later.

18KHarmoni Kerja operator and promoter is keeping update the RECYLCLE information
-------------
Oh yeah.. Yes, It's a CON counter. It's a CONSTRUCTION RELATED counter. He He

@whistlebower99.

Kanger is still in progressing state in its current businesses, which are a bamboo flooring and related products, and Kanger also in its plan to venture in other business activities such as been involved in the construction services, in a process to acquire property for investment and in a final process to acquire a company which involved in a construction material trading.

All sort of the new investments in the new businesses has expanded via internally generated funds or by the issuance of new shares in Kanger. Its not involved any major debt financing facilities and it’s a ZERO RISKS FINANCING exercises . Therefore the company can minimize the risks of higher debt burden by the company in the future. The financing facility via issuance of new shares also could minimize the cost of financing for the company.

If the new businesses are truly have good potential to improve the revenue and profitability of the company

@awesome. A spam counter attacked by a spam.
By the way I held some BPuri shares and have a plan to hold it.
I'm sorry.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
------------

Ya lah betullah tu. Dengar berita dari orang bermuka-muka banyak ni lebih baik JANGAN PERCAYA SAHAJA. MUDAH KAN? He He.

Saya berhenti dahulu lah komen kat sini. Nanti kalau ada berita saya update.

BAGI PELUANG OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 MEROYAN SEPUAS-PUASNYA....

Nanti tolong buat lagilah 10 ID baru ye...

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

Apasal teruk MEROYAN hari ini tu....

Terjerat banyak dekat kaunter ASB ke ???
Sabar ajalah....

@whistlebower99.


Bolehlah awak kaji sedikit siapa substantial holder yang awak maksudkan. Adakah dia sebenarnya genuine shareholder yang beli saham untuk pelaburan atau tidak?

Boleh terangkan sedikit kepada kami semua.


TOLONG KOMEN BERITA YANG POSITIF INI:

BOD sedang meningkatkan peratus pegangan sahamnya dalam syarikat. Setahu saya, ianya amat baik untuk syarikat.

BOD Hj Mazru sudah tingkatkan kepentingan sahamnya ke 14.074%. Memiliki saham sebanyak 557,400,000 unit. Hari ini saja dah tambah share sebanyak 143,000,000 unit saham.
Dia belum pernah jual setakat hari ini.

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183922

FRIENDS:
Kita mungkin boleh perhatikan kebanyakan syarikat yang buat consolidation ialah apabila syarikat mengalami kerugian terkumpul yang banyak selain daripada NOSH yang besar. Banyak syarikat yang mempunyai masalah kerugian terkumpul yang besar akan buat capital reduction bersama-sama dengan proses consolidation.

Dan biasanya, syarikat yang mempunyai BOD yang hanya memiliki peratus saham yang sedikit biasanya suka buat consolidation. Ini kerana kesan negatif consolidation banyak ditanggung oleh pelabur runcit berbanding pemegang saham insider.

NOSH yang besar bukan jadi sebab mewajibkan sesebuah syarikat membuat consolidation. Kecualilah:

1. Keadaan kewangan syarikat amat memerlukan consolidation dibuat, contohnya dalam keadaan kerugian terkumpul yang banyak dalam kunci kira-kira.

2. Atau ada UDANG DISEBALIK BATU dalam kalangan pengurusan sesebuah syarikat tertentu.

JIKA NOSH besar, keadaan kewangan okay, harga saham pun OKAY, syarikat tersebut rasanya tak perlu buat consolidation. LIHAT SAJA CONTOH MY E.G. Bukannya nak buat consolidation tetapi menambahkan lagi jumlah NOSH syarikat sampai 8 bilion unit melalui Bonus Issue.

KAJIAN KES MELIBATKAN NEXGRAM:
1. Nexgram telah melaksanakan capital reduction dan ianya akan secara rasmi diambil kira ke dalam akaun bagi 4QR 2021. Semua kerugian terkumpul akan di offsett dengan perolehan capital reduction dan kunci kira-kira akan mula menunjukkan baki retained earning bermula dalam akaun 4QR 2021.
2. Berlaku perubahan struktur pemegangan saham dalam Nexgram. Pemegang saham dari kalangan BOD telah bertambah, contohnya Hj Mazru telah pegang kepentingan 10.855% dan ianya mungkin akan ditingkatkan sehingga 25% kepentingan saham.

Kesimpulan: Atas dasar tiada lagi masalah kerugian terkumpul yang besar dalam syarikat dan kepentingan saham yang dipegang dari kalangan insider syarikat adalah besar, maka saya rasa kemungkinan syarikat untuk membuat consolidation adalah lebih rendah.

@whistlebower99.

For your information the NOSH of Hong Seng also quite high. It's at 2,457 Million. MY E.G also will have a NOSH of 8 bil + after Bonus Share.

Please do not compare certain company with different management and different problem with ALMOST ALL the companies in FINTECH group...

Please don't ever be A BLIND PARROT spammer anymore. I BEG YOU.

By the way, I also hope you can put Hong Seng and MY E.G in your list of the company which has a big NOSH and has a high risk to do a consolidation.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

BANYAK NEWS TANDANYA NEXGRAM ADA BANYAK BUSINESS SEKARANG.
NEXGRAM SEKARANG BUKAN NEXGRAM DULU.
SELESAI MASALAH YANG DIHADAPI, NEXGRAM BOOOOOOM. HE HE


dan lagi, selepas Bonus Share, MYEG Nosh akan jadi 8 bilion lebih. Bacalah announcement.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------
Pi main jauh-jauh. Pergi jaga ASB....... Kata semalam jual Nexgram beli ASB.

Apa macam sekarang.... Mapoh. Terjerat???

KUALA LUMPUR: Nexgram Holdings Berhad wholly owned subsidiary Associate Partners Laboratories Sdn Bhd (APLab) or (APLSB) on 12 August 2021 and 13 August 2021 has secured two contracts amounted RM57 million for sales and distribution of the Covid-19 consumables in Malaysia.

Of the two contracts, one was the sales contract valued at RM36 million from the procurement agreement of the Covid-19 Antigen Nasal and Saliva Test kits between APLab with the Covid-19 screening test kit distributor Ottigo Sdn Bhd (Ottigo).

APLab on 13 August 2021 also bag a sales contract order from R Clinic amounted RM21 million for the Covid-19 Vaccine Efficacy Antibody Test kits.

Based on the 13 August 2021 announcement at Bursa Malaysia, APLab, a wholly owned subsidiary of Nexgram on 12 August 2021 entered into Master Procurement Agreement (MPA) with Ottigo Sdn Bhd to procure and distribute licensed Covid-19 test consumables using TracVirus Clinic System.

APLab is the authorised seller of Covid-19 screening test consumables namely the Covid-19 related critical-care medical items including RTK Antibody Test Kit, RTK Antigen Nasal Test Kit, RTK Antigen Saliva/Breath Test Kit, quantitative RT-PCR machines, reagents, Neutralising Antibody Test Kit, Al and similar Covid-19 screening test, Professional use Instant Test Kits, parts, systems and solutions. Other Medical Supplies including but not limited to 3-ply Masks, N95 Face Masks, KN95 Face Masks, Surgical Masks, Ventilators, Personal Protective Equipment, Medical Protective Glasses, Disposable Surgical Medical Gown, Sanitizer, Ventilator.

Ottigo is the appointed distributor of APLab, and shall solely procure and distribute all directly or indirectly licensed Covid-19 screening test consumables using Tracvirus Clinic System from APLab. All procurement of consumable materials shall be supplied by APLab and the right are granted to Ottigo to sell and distribution the products in Malaysia.

Ottigo undertake to procure and distribution on Covid-19 screening test solution, subject to force majeure and market condition beyond natural control, in particular Covid-19 solutions, from APLSB Tracvirus Clinic System within twenty four (24) months, whereas sales across APLab’s existing direct clients shall consolidate to the Distributor as the master distributor for ease of on-going business management.

Based on the reports, the term of the MPA shall be for a period of two (2) years and shall thereafter continue in effect on auto renewal on a yearly basis. The contracts is expected to contribute positively to the earnings of the Nexgram Group during the tenure of the agreements.

Source: https://klse.i3investor.com/blogs/mzm511/2021-08-14-story-h1569741320-NEXGRAM_bags_RM57_million_contract_for_distribution_of_the_Covid_19_con.jsp

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------
Pergi jaga ASB....... He He He

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

CUT LOSS NAK BAGI KAMU BELI HARGA MURAH KE???
BUKANNYA NEXGRAM NAK BANGKRAP PUN.
ISU SETTLE, NAIKLAH HARGA DIA..

WHAT AN OPPORTUNIST........ HE HE


BEGINILAH OPPORTUNIST INI CARI MAKAN.
TIMBULKAN KETAKUTAN DEMI MENCAPAI HASRAT CARI MAKAN MELALUI TINDAKAN SPEKULATIF MEREKA.

Nexgram SHARES From UNDER 3 billions increase to 3.8 billions.....MYEG Baru 3.6 billions BOH...ITU MYEG boh!!! NOT CAP AYAM!!!!Means your share in this CAP AYAM KAPUTT is CAIR/DILUTED.....
----------------
Selepas Bonus Share, MYEG Nosh akan jadi 8 bilion lebih. Bacalah announcement.

@hlh1965. Ex-date 27/8/2021 means those who buy the share on 27/8/2021 will not get the right for the RI shares. Only the existing units of shares held up to 30/8/2021 or the units bought on 26/8/2021 will be given the right of the RI shares.

The unit of share bought on 26/8/2021 will be added in the investor's CDS account only on 30/8/2028. The right or OR on the basis of 1 right for every existing 1 share will be given for the shares held on the entitlement date,30 Aug 2021.

Ex-Date 27 Aug 2021
Entitlement date 30 Aug 2021

1. We can sell the shares after 30/8/2021, and that time we already entitled for the right.
2. Free warrants will be given only when we subscribe the RI shares.

***REMARKS: I hope our sifu can correct me if I was wrong.

assell is the RI is rm0.06 ?
-----
YES

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

BANYAK NEWS TANDANYA NEXGRAM ADA BANYAK BUSINESS SEKARANG.
NEXGRAM SEKARANG BUKAN NEXGRAM DULU.
SELESAI MASALAH YANG DIHADAPI, NEXGRAM BOOOOOOM. HE HE

@TwaHuat. Saya rasalah, kalau tengok macam mana Nexgram dapat peluang untuk jadi sistem rasmi kerajaan bagi TracAPM- SafeTravelPass itu hari setelah mungkin bersaing dengan sistem MYEG, saya rasa pihak yang kuat menyokong Nexgram mungkin bekas menteri tugas-tugas khas dari Bersatu yang menjaga APM.

Satu lagi menteri tersebut, Mohd Redzuan adalah orang Melaka. Jadi saya terfikir juga bagaimana plan projek besar di Melaka itu di buat di Melaka. Macam ada kaitan sahaja.

MASTER PROCUREMENT AGREEMENT ENTERED INTO BETWEEN ASSOCIATE PARTNERS LABORATORIES SDN BHD ("APLSB"), A WHOLLY OWNED SUB-SUBSIDIARY WITH RELIABLE HEALTHCARE SDN BHD ("RHSB") TO PROCURE AND DISTRIBUTE APPROVED COVID-19 VACCINE EFFICACY ANTIBODY AND SALIVA ANTIGEN TEST KITS

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183688..

MASTER PROCUREMENT AGREEMENT ENTERED INTO BETWEEN ASSOCIATE PARTNERS LABORATORIES SDN BHD ("APLSB"), A WHOLLY OWNED SUB-SUBSIDIARY WITH RELIABLE HEALTHCARE SDN BHD ("RHSB") TO PROCURE AND DISTRIBUTE APPROVED COVID-19 VACCINE EFFICACY ANTIBODY AND SALIVA ANTIGEN TEST KITS

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183688